- Levamisole
- Levamisole hydrochloride
- Levamisole phosphate
- 165963-57-52-methyl-2,5-adamantanediol
- 16596-41-11-Pyrrolidinamine
- 165966-98-32,8-Methano-2H-1-benzopyran-5,7(3H,4aH)-dione,tetrahydro-8a-hydroxy-6-(hydroxyphenylmethylene)-2-methyl-4a,8-bis(3-methyl-2-buten-1-yl)-3-(3-methyl-3-buten-1-yl)-,(2R,3R,4aR,6E,8S,8aR)-
- 16597-50-5L-Threonine,N-[(phenylmethoxy)carbonyl]-, phenylmethyl ester
- 16599-33-0Methanesulfonothioicacid, S-(2-aminoethyl) ester, hydrobromide (1:1)
- 16600-12-71-Methyl-4-(phenylazo)-quinolinium perchlorate
- 16600-22-93-Quinolinecarboxylicacid, 7-chloro-4-hydroxy-, ethyl ester
- 1660-04-41-Adamantyl methyl ketone
- 16600-92-31,3,5-Benzenetriol,2-nitro-
Hot Products
- 16611-15-74-chloro-2-nitro-N-phenylaniline
- 166113-90-23-Amino-6,7-dihydro-5H-cyclopenta[b]thieno-[3,2-e]pyridine-2-carboxylic acid
- 1662688-20-1
- 16627-71-71H,1H,5H-Perfluoropentyl-1,1,2,2-tetrafluoroethylether
- 166330-10-5(OXYDI-2,1-PHENYLENE)BIS(DIPHENYLPHOSPHINE)
- 1666-13-3Diphenyl diselenide
- 166736-08-9Oxirane, 2-methyl-, polymer with oxirane, mono(2-propylheptyl) ether
- 16679-58-6Desmopressin
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Levamisole hydrochloride |
EINECS | 240-654-6 |
| CAS No. | 16595-80-5 | Density | N/A |
| PSA | 40.90000 | LogP | 2.32160 |
| Solubility | 210 g/L (20 ºC) in water | Melting Point |
266-267 ºC |
| Formula | C11H12N2S.HCl | Boiling Point | 344.4 ºC at 760 mmHg |
| Molecular Weight | 240.757 | Flash Point | 162.1 ºC |
| Transport Information | UN 2811 6.1/PG 3 | Appearance | white to almost white crystalline powder |
| Safety | 36/37/39-45-28A-36 | Risk Codes | 25-20/21/22 |
| Molecular Structure |
|
Hazard Symbols |
 T, Xn
|
| Synonyms |
Imidazo[2,1-b]thiazole, 2,3,5, 6-tetrahydro-6-phenyl-, monohydrochloride, (-)-;Decaris;Prestwick_294;Tramisole;2,3,5,6-Tetrahydro-6-phenyl-imidazo[2,1-b]thiazole, (S)-;L(-)-Levamisole;Niratic-PurOn hydrochloride;(7S)-7-phenyl-4-thia-1,6-diazabicyclo[3.3.0]oct-5-ene hydrochloride;Tramisol;Ergamisol (TN);L-Tetramisole hydrochloride;Niratic hydrochloride;L-Narpenol;Imidazo[2, 1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, L-(-)-;Ergamisol; |
Article Data | 5 |
Levamisole hydrochloride Synthetic route
| Conditions | Yield |
|---|---|
| With sodium hydroxide In water | 94.2% |
- 14769-73-4
Levamisole
- 16595-80-5
levamisole hydrochloride
| Conditions | Yield |
|---|---|
| Stage #1: Levamisole With sodium metabisulfite; pyrographite In isopropyl alcohol for 0.5h; Stage #2: With hydrogenchloride pH=4 - 5; Time; | 92.1% |
| Conditions | Yield |
|---|---|
| With hydrogenchloride In isopropyl alcohol; toluene Title compound not separated from byproducts; | A 16 g B n/a |
- 16595-80-5
levamisole hydrochloride
- 14769-73-4
Levamisole
| Conditions | Yield |
|---|---|
| With sodium hydroxide In diethyl ether; water Inert atmosphere; | 98% |
| With sodium hydroxide In water pH=12; | 98.32% |
| With sodium hydroxide In diethyl ether; water at 20℃; for 0.166667h; | 91% |
- 15243-33-1
dodecacarbonyl-triangulo-triruthenium
- 16595-80-5
levamisole hydrochloride
| Conditions | Yield |
|---|---|
| In tetrahydrofuran (under N2, Schlenk); mixt. of Ru3(CO)12 and ligand stirred in THF at reflux temp. for 40 min, cooled to room temp., left aside for 24 h; filtered, concd., hexane added, ppt. washed with hexane, dried in vacuo,recrystd. from CH2Cl2-hexane; elem. anal.; | A n/a B 9% |
- 103257-53-0
Ru3(CH3CN)2(CO)10
- 16595-80-5
levamisole hydrochloride
| Conditions | Yield |
|---|---|
| In dichloromethane (under N2, Schlenk); ligand added to CH2Cl2 soln. of Ru3(CO)10(MeCN)2, 2min; TLC on silica gel, heated to reflux for 1 h; |
- 61817-93-4, 146143-79-5, 871132-66-0
Os3(CO)10(CH3CN)2
- 16595-80-5
levamisole hydrochloride
| Conditions | Yield |
|---|---|
| In tetrahydrofuran (under N2, Schlenk); ligand added to THF soln. of Os3(CO)10(MeCN)2, stirred at reflux for 40 min; solvent removed under reduced pressure, residue dissolved in CH2Cl2, silica gel chromy. with hexane:CH2Cl2 4:1, and hexane:CH2Cl2 1:1; elem. anal.; |
| Conditions | Yield |
|---|---|
| Stage #1: trifluorobenzylideneacetone; levamisole hydrochloride With pivaloyl chloride; N-ethyl-N,N-diisopropylamine Stage #2: With 3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidine In dichloromethane at 20℃; for 16h; | A n/a B n/a |
| Conditions | Yield |
|---|---|
| Stage #1: trifluorobenzylideneacetone; levamisole hydrochloride With pivaloyl chloride; N-ethyl-N,N-diisopropylamine Stage #2: With (2S,3R)-3-isopropyl-2-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidine In dichloromethane at -78℃; for 16h; enantioselective reaction; | A n/a B n/a C n/a |
- 16595-80-5
levamisole hydrochloride
- 32339-82-5
levamisole citrate
| Conditions | Yield |
|---|---|
| Multi-step reaction with 2 steps 1: sodium hydroxide / water / pH 12 2: ethanol View Scheme |
Levamisole hydrochloride Chemical Properties
.jpg)
IUPAC Name: (6S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole hydrochloride
Molecular Formula: C11H12N2S.HCl
Molecular Weight: 240.75 g/mol
SMILES: c1([C@H]2CN3CCSC3=N2)ccccc1.Cl
InChI: InChI=1/C11H12N2S.ClH/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10;/h1-5,10H,6-8H2;1H/t10-;/m1./s1
EINECS: 240-654-6
Classification Code: Biological response modifier; Drug / Therapeutic Agent; Human Data; Immunomodulator; Mutation data; Reproductive Effect
Product Categories: API; Asymmetric Synthesis; Synthetic Organic Chemistry; Antibiotic Explorer; Veterinaries; Protein Phosphatase
Melting Point: 266-267 °C(lit.)
alpha: -128 °(c=5, H2O)
refractive index: -126 ° (C=1, H2O)
storage temperature: 0-6 °C
Water Solubility: 210 g/L (20 °C)
Flash Point: 162.1 °C
Enthalpy of Vaporization: 58.83 kJ/mol
Boiling Point: 344.4 °C at 760 mmHg
Vapour Pressure of Levamisole hydrochloride (CAS NO.16595-80-5): 6.61E-05 mmHg at 25 °C
Levamisole hydrochloride Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| frog | LD50 | parenteral | 363mg/kg (363mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 289, Pg. 278, 1987. | |
| mouse | LD50 | intramuscular | 121mg/kg (121mg/kg) | Fortschritte der Medizin. Vol. 94, Pg. 793, 1976. | |
| mouse | LD50 | intraperitoneal | 34mg/kg (34mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982. |
| mouse | LD50 | intravenous | 18mg/kg (18mg/kg) | BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982. |
| mouse | LD50 | oral | 223mg/kg (223mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982. |
| mouse | LD50 | subcutaneous | 52mg/kg (52mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982. |
| rat | LD50 | intraperitoneal | 42mg/kg (42mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982. |
| rat | LD50 | intravenous | 26mg/kg (26mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982. |
| rat | LD50 | oral | 180mg/kg (180mg/kg) | Archives of Toxicology. Vol. 54, Pg. 275, 1983. | |
| rat | LD50 | subcutaneous | 80mg/kg (80mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 10, Pg. 3141, 1982. |
| women | TDLo | oral | 180mg/kg/36D (180mg/kg) | BLOOD: THROMBOCYTOPENIA | British Medical Journal. Vol. 2, Pg. 555, 1977. |
Levamisole hydrochloride Safety Profile
Poison by ingestion, intraperitoneal, subcutaneous, intravenous, and intramuscular routes. An experimental teratogen. Human systemic effects by ingestion: thrombocytopenia. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits very toxic fumes of NOx, SOx, and HCl.
Hazard Codes: 
T,
Xn
Risk Statements: 25-20/21/22
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed.
R25 :Toxic if swallowed.
Safety Statements: 36/37/39-45-28A-36
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S28:After contact with skin, wash immediately with plenty of soap-suds.
S36:Wear suitable protective clothing.
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 3
RTECS: NJ5960000
HazardClass: 6.1(b)
PackingGroup of Levamisole hydrochloride (CAS NO.16595-80-5): III
Levamisole hydrochloride Specification
Levamisole hydrochloride (CAS NO.16595-80-5), its Synonyms are (-)-2,3,5,6-Tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride ; Ascaridil ; Citarin L ; Decaris ; Ergamisol ' Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (S)- ; Levamisole HCl ; Imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (-)- (8CI) . It is white to almost white crystalline powder.
What can I do for you?
Get Best Price
